Manufacturing vaccines during Covid-19: CMOs/CDMOs to the rescue
Seeing good demand for biologics manufacturing- Syngene CEO Jonathan Hunt
Scientific breadth-depth of our portfolio contributing to developmentof new therapies- Mahesh Bhalgat
Syngene CEO on what sets Indian CROs apart
Syngene client Dyadic announces development of COVID-19 vaccine in India
Syngene’s client Panbela announces issuance of key U.S. patent for pancreatic cancer
Syngene’s Hunt Says India Now Offers Intellectual Arbitrage to Firms
Remdesivir production boosted our June quarter growth strongly-Syngene CEO
Syngene in Fortune India’s Top 100 wealth creators list
Syngene sees ‘mid-teen’ growth this fiscal on strong pent-up demand
